Vaccines

J&J is evaluating both 1- and 2-dose regimens of the adenovirus vector investigational vaccine.

What the AstraZeneca vaccine research pause meant for physician-patient discussion on vaccine candidate safety.

What we've seen non-immunized communities do for previously eradicated outbreaks.

The logistics of supplying the vaccine are being handled by a collaboration of federal agencies. The DoD, parts of HHS, and CDC are coordinating supply, production, and distribution.

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

A new study in The Lancet maps trends in vaccine confidence around the world.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

Walter A. Orenstein, MD, answers audience questions collected during our Vaccine Race webinar.

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.

BARDA is committing over $1 billion for the agreement, which is dependent on approval or emergency use authorization by the US FDA.

Manufacturers announce their supplies are being sent out for the upcoming season.

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.

What role does new research play in combating public vaccination concerns?

A discussion on the process by which the FDA regulates vaccine candidates at a time when COVID-19 candidates are progressing.

Dr. Adam Brufsky, an oncologist, compares viral and cancer immunity. Dr. Patrick Soon-Shiong connects the relation to COVID-19 vaccine research.

What happens if we don't get a COVID-19 vaccine? Patrick Soon-Shiong, MD, describes another potential route for research efforts, which could also supplement vaccine development.

Dr. Patrick Soon-Shiong and Dr. Adam Brufsky move on from the messenger RNA candidates to the adenovirus vaccines.

A benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection

Many families fell behind on vaccines during the pandemic, but a study finds most clinics are available to schedule make-up appointments.

A single injection of the Ad5-vectored COVID-19 vaccine induced specific immune responses to the spike glycoprotein at day 28.

The development of BNT162 is based on BioNTech’s mRNA platform; the vaccine will then be produced using Pfizer’s vaccine manufacturing capacities.

The European Commission has granted Marketing Authorization for a 2-dose Ebola vaccine regimen.